Synairgen (GB:SNG) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Synairgen plc has announced that Dr. Phillip Monk will be stepping down from the company’s Board after 18 years, effective December 31, 2024. Dr. Marcin Mankowski, who became Chief Medical Officer in 2023, will continue leading the clinical development of SNG001, Synairgen’s investigational inhaled antiviral treatment. The company also hints at upcoming Board changes as it prepares for its Annual General Meeting in early October.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.